Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    A Sampling of Highlights from the Literature
    Cancer Immunol Res February 1 2021 9 (2) 127-127;

In the Spotlight

  • In the Spotlight
    Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2
    Kerry S. Campbell
    Cancer Immunol Res February 1 2021 9 (2) 128-128; DOI:10.1158/2326-6066.CIR-20-0996

Masters of Immunology

  • Masters of Immunology
    About the Master
    Cancer Immunol Res February 1 2021 9 (2) 129-129; DOI:10.1158/2326-6066.CIR-20-0900

  • Masters of Immunology
    Health and Fitness at the Single-Cell Level
    Douglas R. Green
    Cancer Immunol Res February 1 2021 9 (2) 130-135; DOI:10.1158/2326-6066.CIR-20-0418

Priority Briefs

  • Priority Briefs | AuthorChoice
    Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
    Emily J. Lelliott, Stefano Mangiola, Kelly M. Ramsbottom, Magnus Zethoven, Lydia Lim, Peter K.H. Lau, Amanda J. Oliver, Luciano G. Martelotto, Laura Kirby, Claire Martin, Riyaben P. Patel, Alison Slater, Carleen Cullinane, Anthony T. Papenfuss, Nicole M. Haynes, Grant A. McArthur, Jane Oliaro and Karen E. Sheppard
    Cancer Immunol Res February 1 2021 9 (2) 136-146; DOI:10.1158/2326-6066.CIR-20-0401

    Combined BRAF, MEK, and CDK4/6 inhibition is being tested in clinical trials for treating melanoma. The authors show this combination depletes tumor-associated myeloid cells in the tumor immune microenvironment, which renders tumors unresponsive to immune checkpoint blockade.

  • Priority Briefs
    Kindlin3-Dependent CD11b/CD18-Integrin Activation Is Required for Potentiation of Neutrophil Cytotoxicity by CD47–SIRPα Checkpoint Disruption
    Panagiota Bouti, Xi Wen Zhao, Paul J.J.H. Verkuijlen, Anton T.J. Tool, Michel van Houdt, Nezihe Köker, Mustafa Yavuz Köker, Ozlem Keskin, Sinan Akbayram, Robin van Bruggen, Taco W. Kuijpers, Hanke L. Matlung and Timo K. van den Berg
    Cancer Immunol Res February 1 2021 9 (2) 147-155; DOI:10.1158/2326-6066.CIR-20-0491

    Neutrophil-mediated ADCC is dependent on CD11b/CD18-integrin–mediated conjugate formation and is controlled by CD47–SIRPα signaling. By using LAD3-derived neutrophils, it is demonstrated that CD47–SIRPα signaling controls CD11b/CD18-integrin inside-out activation during conjugate formation in a kindlin3-dependent manner.

Research Articles

  • Research Articles
    KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
    Rupal S. Bhatt, Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman, Chun-Hau Chen, Opeyemi A. Jegede, Paul J. Catalano, Jean-Christophe Pignon, Maura Sticco-Ivins, Baogong Zhu, Ping Hua, Jo Soden, Jie Zhu, David F. McDermott, Antonio R. Arulanandam, Sabina Signoretti and Gordon J. Freeman
    Cancer Immunol Res February 1 2021 9 (2) 156-169; DOI:10.1158/2326-6066.CIR-20-0315

    The B7 family member HHLA2 delivers costimulatory signals via TMIGD2. The data show that KIR3DL3 is an inhibitory receptor for HHLA2 and that HHLA2 is expressed in kidney cancer separately from PDL1; targeting this interaction could be immunotherapeutic.

  • Research Articles
    Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors
    Irene Veneziani, Paola Infante, Elisa Ferretti, Ombretta Melaiu, Cecilia Battistelli, Valeria Lucarini, Mirco Compagnone, Carmine Nicoletti, Aurora Castellano, Stefania Petrini, Marzia Ognibene, Annalisa Pezzolo, Lucia Di Marcotullio, Roberto Bei, Lorenzo Moretta, Vito Pistoia, Doriana Fruci, Vincenzo Barnaba, Franco Locatelli and Loredana Cifaldi
    Cancer Immunol Res February 1 2021 9 (2) 170-183; DOI:10.1158/2326-6066.CIR-20-0313

    Nutlin-3a, a small molecule antagonizing the inhibitory MDM2–p53 interaction, has a p53-dependent immunomodulatory effect on neuroblastoma. Nutlin-3a increases neuroblastoma's susceptibility to NK-cell killing, highlighting how this compound could be prospectively employed for an NK cell–based immunotherapy.

  • Research Articles
    Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells
    Jefte M. Drijvers, Jacob E. Gillis, Tara Muijlwijk, Thao H. Nguyen, Emily F. Gaudiano, Isaac S. Harris, Martin W. LaFleur, Alison E. Ringel, Cong-Hui Yao, Kiran Kurmi, Vikram R. Juneja, Justin D. Trombley, Marcia C. Haigis and Arlene H. Sharpe
    Cancer Immunol Res February 1 2021 9 (2) 184-199; DOI:10.1158/2326-6066.CIR-20-0384

    It is challenging to develop metabolism-targeted therapeutics because T cells and cancer cells have similar metabolic properties. The authors develop an in vitro pharmacologic screening platform and highlight ferroptosis as a metabolic vulnerability of CD8+ T cells.

  • Research Articles
    Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity
    Jinming Yang, Chi Yan, Anna E. Vilgelm, Sheau-Chiann Chen, Gregory D. Ayers, Christopher A. Johnson and Ann Richmond
    Cancer Immunol Res February 1 2021 9 (2) 200-213; DOI:10.1158/2326-6066.CIR-20-0312

    Myeloid cell CXCR2 affects not only suppressive MDSCs but also B cells, especially the B1b subset. CXCL11-producing B cells are key and impact infiltration and activation of effector CD8+ T cells in the tumor microenvironment.

  • Research Articles
    Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity
    Niloufar Khojandi, Lindsey M. Kuehm, Alexander Piening, Maureen J. Donlin, Eddy C. Hsueh, Theresa L. Schwartz, Kaitlin Farrell, John M. Richart, Elizabeth Geerling, Amelia K. Pinto, Sarah L. George, Carolyn J. Albert, David A. Ford, Xiufen Chen, Justin Kline and Ryan M. Teague
    Cancer Immunol Res February 1 2021 9 (2) 214-226; DOI:10.1158/2326-6066.CIR-20-0358

    The influence of obesity on cancer immunotherapy is not clear. This study shows oxidized LDL promotes resistance to immunotherapy by suppressing T-cell function and driving tumor cytoprotection mediated by heme oxygenase-1 (HO-1), suggesting HO-1 is a promising therapeutic target.

  • Research Articles
    Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy
    Lindsey M. Kuehm, Niloufar Khojandi, Alexander Piening, Lauryn E. Klevorn, Simone C. Geraud, Nicole R. McLaughlin, Kristine Griffett, Thomas P. Burris, Kelly D. Pyles, Afton M. Nelson, Mary L. Preuss, Kevin A. Bockerstett, Maureen J. Donlin, Kyle S. McCommis, Richard J. DiPaolo and Ryan M. Teague
    Cancer Immunol Res February 1 2021 9 (2) 227-238; DOI:10.1158/2326-6066.CIR-20-0396

    Dietary fructose can be utilized by tumor cells and promotes cytoprotection by inducing HO-1 expression, thereby impacting TIL responses and immunotherapy outcomes. The data highlight a novel immune evasion mechanism and a potential therapeutic target.

  • Research Articles
    Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune–Tumor Interactions: Engage, Expand, Enable
    Kellsye P. Fabian, Anthony S. Malamas, Michelle R. Padget, Kristen Solocinski, Benjamin Wolfson, Rika Fujii, Houssein Abdul Sater, Jeffrey Schlom and James W. Hodge
    Cancer Immunol Res February 1 2021 9 (2) 239-252; DOI:10.1158/2326-6066.CIR-20-0638

    Treatment of established tumors with a combination “pentatherapy” regimen leads to T-cell activation while decreasing Treg suppression. The data highlight how the combination of multimodal immunotherapy agents can engage, enhance, and enable adaptive antitumor responses.

Back to top
PreviousNext
Cancer Immunology Research: 9 (2)
February 2021
Volume 9, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • In the Spotlight
  • Masters of Immunology
  • Priority Briefs
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Characterization of Murine Syngeneic Tumor Models
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement